// STATE LEGISLATION TRACKER

Arizona HB 4036: bulk drug substances; prohibitions

⚖️ MIXED for peptide users 👤 LOW user impact 📜 Status: Failed

State: Arizona
Bill: HB 4036
Session: 57th-2nd-regular
Filed: 2026-02-09
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Arizona HB4036 would have added state rules for compounded obesity and weight-management drugs made from bulk drug substances, especially GLP-1 and GIP receptor agonists. It would have required pharmaceutical-grade sourcing, certificates of analysis, quality testing, records, inspections, truthful advertising, and penalties for violations. The bill failed, so it does not currently change peptide access in Arizona.

Key Points

Targets compounded GLP-1 and GIP obesity drugs, not all peptides
Would add sourcing, COA, testing, and recordkeeping duties
Could raise costs or limit some compounded weight-loss peptide access
Would give Arizona pharmacy regulators more inspection authority
No clear change to NP, naturopathic, telehealth, PDMP, or controlled substance rules

What to Watch For

Concern Similar bills could return and make compounded GLP-1 or GIP access harder or more expensive.

✓

Opportunity Quality testing and sourcing rules could reduce risk from low-grade or misleading compounded products.

Note This bill focused on pharmacy compounding, not prescriber scope or telehealth practice.

Where the Bill Stands

The bill failed in the 2026 Arizona legislative session and is not active law.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-10-02 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws